Special Issue "Toxoplasma Infection: Current Problems, Progress and New Challenges"
Deadline for manuscript submissions: 15 December 2023 | Viewed by 7745
Interests: Toxoplasma gondii; zoonotic parasites
Interests: new insights in pathogenesis; new evidence on the epidemiology of T. gondii strains and toxoplasma infections; novel diagnostics; empirical data on the clinical spectrum of disease; toxoplasmosis outcomes and effectiveness of preventive/therapeutic strategies; novel drugs; vaccines
Special Issues, Collections and Topics in MDPI journals
Toxoplasma gondii is one of the most evolutionarily successful pathogens on earth, infecting all warm-blooded animals, and can be found on every continent of the globe. Cats, the definitive host of T. gondii, can shed millions of hardy oocysts into the environment. Intermediate hosts including humans and animals accidentally ingest these oocysts and acquire infection. The number of domestic cats is rising worldwide, which inevitably favors T. gondii transmission. Recent studies have proposed that the historical expansion of domestic cats engendered the global dissemination of clonal lineages of T. gondii. Susceptible hosts such as macropods, sea otters, immunocompromised humans, and developing human fetuses are the victims of toxoplasmosis. Recent years have seen the unprecedented uncovering of the global genetic diversity of T. gondii, which aids in the development of treatment methods. Progress has been made in exploring various drug classes with diverse targets. However, while effective in treating T. gondii tachyzoites, current drugs are virtually impotent against cyst-enclosed bradyzoites. Low concentration in the brain and eyes, cytotoxicity, and long treatment durations are among the issues faced with available therapeutics. Searching for compounds with high efficacy and low toxicity is a primary challenge of current T. gondii research. Progress has been made in developing multiple classes of vaccines including DNA vaccines, nanoparticles, and virus-like particle vaccines. Live-attenuated vaccines have proven more immunogenic than these other classes, but due to safety issues, their usage in humans is not considered practical. Alternatively, vaccination of definitive hosts to prevent oocyst shedding could be a promising route of transmission-blocking.
Dr. Tiantian Jiang
Dr. Despina G. Contopoulos-Ioannidis
Dr. Shwab Keats
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- environmental transmission
- genetic diversity
- vaccine development
- drug discovery